@article{4cc64401773a4de787c219ada4e7dd57,
title = "Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer{\textquoteright}s Disease",
abstract = "The aim of this study was to describe sex differences in neuropsychiatric symptoms (NPSs) in patients with Alzheimer{\textquoteright}s disease (AD). Baseline scores on the Cohen-Mansfield Agitation Inventory, Neurobehavioral Rating Scale–Agitation subscale, and the Neuropsychiatric Inventory from patients with AD enrolled in a multicenter trial of citalopram for the treatment of agitation were analyzed. We found not only that patients with AD having agitation were likely to exhibit many other NPSs but also that the women in this study were more likely to exhibit a broader range of NPS than were the men. These results suggest greater heterogeneity in the clinical presentation of women compared to men, and thus in the potential targets for treatment in these patients. Further characterization of sex differences in NPS can inform future efforts aimed at establishing subtypes of patients for whom various treatment approaches will be most appropriate.",
keywords = "Alzheimer disease, agitation, behavioral disturbance, gender difference, neuropsychiatric",
author = "Ye Tao and Peters, {Matthew E.} and Drye, {Lea T.} and Devanand, {Davangere P.} and Mintzer, {Jacobo E.} and Pollock, {Bruce G.} and Porsteinsson, {Anton P.} and Rosenberg, {Paul B.} and Schneider, {Lon S.} and Shade, {David M.} and Daniel Weintraub and Jerome Yesavage and Lyketsos, {Constantine G.} and Munro, {Cynthia A.}",
note = "Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: National Institute on Aging and National Institute of Mental Health, R01AG031348. Dr Porsteinsson reports receiving research funding from Avanir, Baxter, BMS, Elan, EnVivo, Genentech/Roche, Janssen Alzheimer Initiative, Merck, Pfizer, Toyama, Medivation, National Institutes of Health (NIH), and Department of Defense. Dr Devanand reports receiving grant funding from the NIH and Eli Lilly. Dr Mintzer reports receiving research funding from Accera, Avanir, Baxter, Elan, Eli Lilly, F. Hoffmann-La Roche, Genentech, Janssen Alzheimer Initiative, Merck, Novartis, Pfizer, Takeda Global Research & Development Center, Wyeth, and NIH; Dr Munro reports receiving grant funding from the NIH; being paid for expert testimony from various law firms, Office of Federal Public Defender, and US Attorney{\textquoteright}s Office; and being paid for lectures for Episcopal Ministries. Dr Schneider reports receiving grant funding from the NIH. Dr Lyketsos reports receiving grant funding from the NIH; is a paid consultant for Avanir, BMS, Elan, Eli Lilly, Genentech, GSK, Janssen, Novartis, NFL, and Pfizer. Dr Rosenberg reports receiving research funding from Elan, Eli Lilly, Merck, and Functional Neuromodulation, Inc. Publisher Copyright: {\textcopyright} The Author(s) 2018.",
year = "2018",
month = nov,
day = "1",
doi = "10.1177/1533317518783278",
language = "English (US)",
volume = "33",
pages = "450--457",
journal = "American Journal of Alzheimer's Disease and Other Dementias",
issn = "1533-3175",
publisher = "SAGE Publications Inc.",
number = "7",
}